ALSO NOTED: Jerini to open US subsidiary;La Jolla adds to Riquent data;and much more...

> Jerini is establishing a U.S. subsidiary, Jerini Ophthalmic, which will focus on the development of new therapeutics for eye diseases. Dr. Anthony P. Adamis (co-founder of Eyetech Pharmaceuticals) will head Jerini Ophthalmic as president and CEO. Report

> La Jolla Pharmaceutical has provided updated interim data on Riquent which supports a significant dose response to the drug. Report

> India's Jubilant Organosys says it has received $60 million in contracts for research and manufacturing services. Article

> Cell Therapeutics announced it will file for a Special Protocol Assessment for the design of a phase III trial of a combination therapy for women with advanced lung cancer. Release

> A growing number of prominent scientists are raising serious criticisms about the government's $1.5 billion Cancer Genome Atlas, calling it a waste of money at a time when federal funding for science is facing a critical challenge. Report

> France's ExonHit Therapeutics says it could have a diagnostic test that can identify Alzheimer's. Report

> A research group at Washington University School of Medicine in St. Louis has found that two anti-epileptic drugs can prevent permanent hearing loss to a significant degree in mice exposed to loud noises. Report

And Finally... The outbreak of a deadly form of tuberculosis indicates that the international program intended to control the disease has broken down. Article

Suggested Articles

Merck’s TIGIT-blocking prospect and PD-1 med Keytruda shrank tumors in 29% of lung cancer patients who had never tried a checkpoint inhibitor.

Merck's HIF-2α inhibitor, picked up in its $1 billion Peloton buyout, shrank kidney tumors in 36% of patients and showed promise in other tumors, too.

Amunix reported that a single dose of its lead T-cell engager caused caused large HER2-positive tumors to shrink in mice.